Physician profile
Chad J Long
NPI 1801865142
$4,577.94
in general payments reported to CMS, 2019-2025
26 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $387 · 2021: $360 · 2022: $558 · 2023: $1,020 · 2024: $991 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $13.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.95 |
| Education | $13.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,278.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $965.28 | 2020-2025 | Xifaxan |
| Celgene Corporation | $609.20 | 2021-2024 | Zeposia |
| Allergan, INC. | $300.19 | 2019-2020 | |
| Pfizer INC. | $296.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.32 | 2019-2024 | Eohilia, Entyvio |
| Aimmune Therapeutics, INC. | $142.78 | 2024-2025 | Zenpep, Vowst |
| Ironwood Pharmaceuticals, INC | $112.81 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $106.75 | 2019-2020 | |
| Janssen Biotech, INC. | $98.39 | 2024-2025 | Tremfya, Stelara |
| Romark Laboratories, Lc | $73.22 | 2019-2020 | |
| Ardelyx, INC. | $59.08 | 2023-2024 | Ibsrela |
| Braintree Laboratories, INC. | $54.19 | 2023 | Sutab, Suflave |
| Medtronic, INC. | $46.87 | 2024 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $34.20 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.83 | 2023 | Dupixent |
| Madrigal Pharmaceuticals | $24.97 | 2024 | Resmetirom |
| Organon LLC | $23.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.60 | 2023 | Cyltezo |
| Qol Medical, LLC | $19.60 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $16.03 | 2022 | |
| Redhill Biopharma INC. | $15.56 | 2023 | Movantik, Aemcolo, Talicia |
| Celltrion USA INC. | $13.85 | 2023 | Yuflyma |
| Alfasigma USA, INC. | $11.47 | 2020 | |
| Merck Sharp & Dohme LLC | $11.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.